Global Heart Stent Market Size By Type (Drug-Eluting Stent, Bare Metal Stent), By Application (Acute Myocardial Infarction, Unstable Angina), By Region, And Segment Forecasts, 2023 to 2032

The Global Heart Stent Market was valued at USD 11.5 billion in 2023 and is projected to surpass USD 19.4 billion by 2031, registering a CAGR of 6.8% during the forecast period (2023-2031). The market is driven by the increasing prevalence of cardiovascular diseases (CVDs), advancements in stent technologies, rising geriatric population, and growing adoption of minimally invasive procedures. Heart stents play a crucial role in treating blocked or narrowed arteries, reducing the risk of heart attacks, and improving patient survival rates.

Growing government healthcare initiatives, expanding insurance coverage, and an increasing number of percutaneous coronary intervention (PCI) procedures are further propelling market demand. The emergence of biodegradable stents, drug-eluting stents (DES), and smart stents with real-time monitoring capabilities is also driving innovation in this sector.

Drivers

1. Rising Prevalence of Cardiovascular Diseases (CVDs)

Cardiovascular diseases are the leading cause of death worldwide, with ischemic heart disease (IHD) and stroke accounting for a significant portion. Factors such as sedentary lifestyles, unhealthy diets, obesity, diabetes, and hypertension are contributing to the growing incidence of heart diseases, fueling the demand for heart stents.

2. Advancements in Stent Technologies

The development of drug-eluting stents (DES), bioresorbable stents, and next-generation polymer-coated stents has significantly improved patient outcomes. These advanced stents reduce restenosis, enhance endothelial healing, and improve long-term efficacy.

3. Growing Preference for Minimally Invasive Procedures

The increasing adoption of minimally invasive procedures like angioplasty with stent placement is a key driver. Compared to traditional open-heart surgery, these procedures involve faster recovery times, reduced hospital stays, and lower complications, making them a preferred treatment option.

4. Expanding Healthcare Infrastructure in Emerging Markets

Emerging economies in Asia-Pacific, Latin America, and the Middle East are witnessing substantial investments in healthcare infrastructure, expanding access to advanced cardiac interventions. Rising disposable incomes and increasing awareness of heart health further support market growth.

Restraints

1. High Cost of Heart Stents

Despite price regulations in some regions, the high cost of advanced heart stents remains a key barrier, particularly in low-income and developing countries. The affordability of procedures continues to be a challenge for uninsured patients.

2. Risks Associated with Stent Implantation

Potential complications, including stent thrombosis, restenosis, bleeding risks, and allergic reactions, can limit the widespread adoption of heart stents. Although newer-generation stents reduce these risks, concerns remain, particularly in high-risk patients.

3. Stringent Regulatory Approvals

The long approval processes imposed by regulatory authorities such as the FDA (USA) and EMA (Europe) pose challenges for market players introducing innovative stent technologies. Compliance with strict safety and efficacy standards slows down the commercialization process.

Opportunity

1. Increasing Demand for Biodegradable and Smart Stents

Biodegradable stents, which dissolve over time after supporting the artery, are gaining traction due to their potential to reduce long-term complications. Additionally, smart stents embedded with sensors for real-time monitoring of arterial conditions represent a significant market opportunity.

2. Rising Investments in R&D

Several medical device companies are investing heavily in research and development to create more effective, safer, and affordable stents. The development of polymer-free drug-eluting stents and nanotechnology-enabled stents presents a lucrative growth opportunity.

3. Favorable Government Policies

Government initiatives promoting affordable healthcare, reimbursement programs, and subsidies for cardiac patients are expected to drive market expansion. Policies aimed at price capping for stents (such as in India and China) make treatments more accessible to the general population.

Market by Product Type Insights

Drug-Eluting Stents (DES): Dominated the market in 2023, owing to their high efficacy in preventing restenosis and lower risk of thrombosis. DES is expected to maintain its dominance due to continuous innovation in polymer technologies.

Bare Metal Stents (BMS): Still used in cases where patients cannot tolerate long-term antiplatelet therapy, but their market share is declining.

Bioresorbable Stents: Emerging as a high-growth segment, driven by their ability to fully degrade in the body after providing structural support.

Market by End-Use Insights

Hospitals: Accounted for the largest revenue share in 2023, as most stent procedures are performed in hospital cardiac catheterization labs.

Specialty Cardiac Centers: Witnessing increasing adoption of advanced stent technologies, particularly in developed markets.

Ambulatory Surgical Centers (ASCs): Expected to grow at a rapid rate, as these facilities offer cost-effective alternatives for stent implantation.

Market by Regional Insights

North America: Led the market in 2023, supported by the high prevalence of heart diseases, advanced healthcare infrastructure, and the presence of major industry players in the U.S. and Canada.

Europe: Holds a significant market share, driven by technological advancements and government-funded healthcare programs.

Asia-Pacific: Expected to register the highest CAGR, with China, India, and Japan emerging as key growth markets due to rapid urbanization, increasing healthcare spending, and government initiatives.

Latin America & Middle East: Experiencing moderate growth, driven by improving healthcare infrastructure and increasing medical tourism.

Competitive Scenario

Key players in the Global Heart Stent Market include:

Abbott Laboratories

Medtronic plc

Boston Scientific Corporation

B. Braun Melsungen AG

Terumo Corporation

BIOTRONIK SE & Co. KG

MicroPort Scientific Corporation

Meril Life Sciences

Cook Medical

STENTYS SA

These companies focus on strategic collaborations, acquisitions, and new product launches to strengthen their market position.

Scope of Work – Global Heart Stent Market

Report Metric Details

Market Size (2023) USD 11.5 Billion

Projected Market Size (2031) USD 19.4 Billion

CAGR (2023-2031) 6.8%

Key Segments Drug-Eluting Stents (DES), Bare Metal Stents (BMS), Bioresorbable Stents

Largest Segment by Product Type Drug-Eluting Stents (DES)

Largest Segment by End-Use Hospitals

Leading Region North America

Key Players Abbott Laboratories, Medtronic, Boston Scientific, B. Braun, Terumo, BIOTRONIK, MicroPort, Cook Medical, Meril Life Sciences

Key Market Developments

March 2023: Abbott Laboratories launched its next-generation biodegradable stent, reducing post-procedure complications.

July 2023: Boston Scientific expanded its drug-eluting stent portfolio, enhancing precision and long-term safety.

November 2023: Medtronic acquired a digital health startup specializing in real-time monitoring of heart stent performance.

January 2024: Terumo Corporation announced a strategic partnership with a biotech firm to develop polymer-free stents.

FAQs

What is the current market size of the Global Heart Stent Market?

The market was valued at USD 11.5 billion in 2023.

What is the major growth driver of the Heart Stent Market?

The increasing prevalence of cardiovascular diseases and advancements in drug-eluting stent (DES) technology.

Which is the largest region during the forecast period in the Heart Stent Market?

North America is expected to lead, with Asia-Pacific registering the highest growth rate.

Which segment accounted for the largest market share in the Heart Stent Market?

Drug-Eluting Stents (DES) dominated the market in 2023.

Who are the key market players in the Heart Stent Market?

Key players include Abbott, Medtronic, Boston Scientific, B. Braun, and Terumo.